Equillium, Inc.
https://equilliumbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Equillium, Inc.
Eight Recent Deals Tapping AI/ML For R&D
Big pharmas, biotechs and the US government look to partner with artificial intelligence and machine learning firms for discovery efforts across therapeutic areas and modalities.
J.P. Morgan Day One: Novartis Reveals Two Deals, Pfizer's Bad Year, Bristol's Wobbly Growth
Daily notebook from the J.P. Morgan Healthcare Conference: Deal and strategy news from Novartis, BMS and Pfizer; Gilead talks lenacapavir PrEP launch plans; BioMarin's new CEO makes an appearance and Saunders explains the status at Bausch + Lomb.
Deal Watch: AbbVie Leads J.P. Morgan Deal Rush, But BI, Genentech And Lilly Also Big Players
As the usual flurry of deals coincides with the J.P. Morgan Healthcare Conference, AbbVie signed an mRNA pact with Anima and a cancer research tie-up with Immunome.
Asia Deal Watch: Kelun Partners With Merck A Third Time, Optioning Rights To Seven ADCs
Already partnered on antibody-drug conjugates and a Phase III breast cancer candidate, Merck could pay up to $9.3bn under its third pact in 2022 with Kelun. Eisai divests Fycompa to Catalyst.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Attenuate Biopharmaceuticals, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice